Evox Therapeutics
At Evox Therapeutics, we focus on tackling genetically defined CNS disorders using exosome-based genome-editing therapeutics. Our lead programs address SCA2/ALS targeting ATXN2 and Huntington’s disease targeting MSH3
)
January 11-14, 2027 | San Francisco
January 11-14, 2027 | San Francisco
)
)
January 11-14, 2027 | San Francisco
){kind=logo}
){kind=logo}
)